Efficacy of Ramipril in Therapy-resistant Hypertension

In an open, 48-week study the antihypertensive efficacy of ramipril when administered as add-on therapy to existing triple antihypertensive treatment (diuretics, beta-blockers, vasodilators) was investigated in 56 patients (24 females, 32 males) with therapy-resistant hypertension. The main variable (sitting diastolic blood pressure) decreased from 112 mmHg at baseline to 91 mmHg at week 8 (p < 0.01) and remained stable thereafter until the end of the trial. The systolic blood pressure in the sitting position decreased from 175 mmHg at baseline to 146 mmHg at week 8 (p < 0.01) and also remained stable thereafter until the end of the trial. Ramipril doses between week 8 and the end of the trial were not changed in 82% of patients. 45% of patients were treated with 5 mg ramipril/day, 33% with 10 mg/day and 22% with 20 mg/day at the end of the study. Addition of ramipril allowed a reduction in the doses of concurrrent therapy, especially in relation to beta-blockers (p < 0.02) and vasodilators (p < 0.01). The safety was good--no serious adverse events were observed. Ramipril is, therefore, a suitable drug for the patients with therapy-resistant hypertension allowing reduction of the doses of concomitant medication.